

# RICHTER GEDEON VEGYESZETI GYAR NYRT

ISIN: HU0000123096 WKN: 4042387 Asset Class: Stock

|                   |                      |
|-------------------|----------------------|
| <b>Company</b>    | 2024/08/16 10:08:58  |
| <b>Price</b>      | <b>10,460.00</b>     |
|                   | HUF                  |
| <b>Difference</b> | <b>0.97%(100.00)</b> |



## Contact Details

|                                      |  |
|--------------------------------------|--|
| CHEMICAL WORKS OF GEDEON RICHTER PLC | Tel: +36-1-431-4000  |
| --                                   | Fax: +36-1-260-6650  |
| Gyömrői út 19-21                     | Web: <a href="http://www.richter.hu">http://www.richter.hu</a> |
| 1103 Budapest                        | E-mail: <a href="mailto:posta@richter.hu">posta@richter.hu</a> |

## Company Profile

Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023              |                        | 2022              |                        | 2021              |                        |
|---------------------------------------|-------------------|------------------------|-------------------|------------------------|-------------------|------------------------|
|                                       | Assets            | Liabilities and equity | Assets            | Liabilities and equity | Assets            | Liabilities and equity |
| <b>Current assets</b>                 | 534,913,000,000   |                        | 575,770,000,000   |                        | 412,622,000,000   |                        |
| <b>Common stock capital</b>           |                   | 18,638,000,000         |                   | 18,638,000,000         |                   | 18,638,000,000         |
| <b>Fixed assets</b>                   | 826,304,000,000   |                        | 764,519,000,000   |                        | 732,660,000,000   |                        |
| <b>Equity capital of a company</b>    |                   | 1,142,581,000,000      |                   | 1,060,352,000,000      |                   | 923,022,000,000        |
| <b>Cash and cash equivalents</b>      | 80,493,000,000    |                        | 79,719,000,000    |                        | 59,856,000,000    |                        |
| <b>Accrued liabilities</b>            |                   | 6,559,000,000          |                   | 5,079,000,000          |                   | 5,878,000,000          |
| <b>Other assets</b>                   | -                 |                        | -                 |                        | -                 |                        |
| <b>Current liabilities</b>            |                   | 114,508,000,000        |                   | 179,507,000,000        |                   | 123,213,000,000        |
| <b>Prepayments and accrued income</b> | -                 |                        | -                 |                        | -                 |                        |
| <b>Non-current liabilities</b>        |                   | 94,720,000,000         |                   | 91,997,000,000         |                   | 92,153,000,000         |
| <b>Different income</b>               |                   | -                      |                   | -                      |                   | -                      |
| <b>Other liabilities</b>              |                   | 17,723,000,000         |                   | 32,358,000,000         |                   | 15,287,000,000         |
| <b>Total assets</b>                   | 1,361,217,000,000 | 1,361,217,000,000      | 1,340,289,000,000 | 1,340,289,000,000      | 1,145,282,000,000 | 1,145,282,000,000      |

## Balance notes

|                            | 2023   | 2022   | 2021   |
|----------------------------|--------|--------|--------|
| <b>Accounting standard</b> | IFRS   | IFRS   | IFRS   |
| <b>Employees</b>           | 11,603 | 12,167 | 12,262 |
| <b>Equity ratio</b>        | 84.80% | 79.89% | 81.30% |
| <b>Debt-equity ratio</b>   | 17.92% | 25.17% | 23.00% |

## Others

|                         | 2023  | 2022  | 2021  |
|-------------------------|-------|-------|-------|
| <b>Tax Expense Rate</b> | 6.58% | 5.27% | 3.76% |

# RICHTER GEDEON VEGYESZETI GYAR NYRT

ISIN: HU0000123096 WKN: 4042387 Asset Class: Stock

## Income statement

|  | 2023            | 2022            | 2021            |
|--|-----------------|-----------------|-----------------|
| <b>Turnover</b>  | 805,158,000,000 | 802,755,000,000 | 630,595,000,000 |
| <b>Net income</b>  | 158,850,000,000 | 155,581,000,000 | 139,626,000,000 |
| <b>EBIT</b>  | 389,755,000     | 385,312,500     | 352,945,000     |
| <b>Operating income before taxes</b>                                 | 165,406,000,000 | 159,513,000,000 | 143,465,000,000 |
| <b>Cash Flow</b>   | 148,535,000,000 | 198,388,000,000 | 142,863,000,000 |
| <b>Net interest income</b>   | 9,504,000,000   | 5,388,000,000   | 2,287,000,000   |
| <b>Research and development expenses</b>                             | 78,344,000,000  | 75,109,000,000  | 61,005,000,000  |
| <b>Income taxes</b>  | 10,889,000,000  | 8,408,000,000   | 5,395,000,000   |
| <b>Result from investments in subsidiaries, associates and other</b> | 6,134,000,000   | 6,150,000,000   | 3,110,000,000   |
| <b>Revenues per employee</b>   | 173,481         | 164,945         | 128,567         |

## Board of Directors

|                        |                               |
|------------------------|-------------------------------|
| Livia Pavlik           | Chairman of Supervisory Board |
| Szilveszter Vizi       | Chairman of Supervisory Board |
| Anett Pandurics        | Member of Supervisory Board   |
| Ilona Hardy            | Member of Supervisory Board   |
| Pal Nandor             | Member of Supervisory Board   |
| Péter Cserhádi         | Member of Supervisory Board   |
| Róbert Jonathán Bedros | Member of Supervisory Board   |
| Balazs Szepesi         | Member of Supervisory Board   |
| Bálint Szécsényi       | Member of Supervisory Board   |
| Dale Martin            | Member of Supervisory Board   |
| Erik Bogsch            | Member of Supervisory Board   |
| Ferenc Sallai          | Member of Supervisory Board   |
| Gabriella Balogh       | Member of Supervisory Board   |
| Gal Krisztina          | Member of Supervisory Board   |
| István Hamecz          | Member of Supervisory Board   |
| Laszlo Nemeth          | Member of Supervisory Board   |

## Members of Management Board

|                |                               |
|----------------|-------------------------------|
| Gábor Orbán    | Chairman of Managing Board    |
| Istvan Greiner | Member of Executive Committee |
| Attila Szenasi | Member of Executive Committee |
| Istvan Hamecz  | Member of Executive Committee |
| Katalin Erdei  | Member of Executive Committee |
| Tamas Szolyak  | Member of Executive Committee |
| Tibor Horvath  | Member of Executive Committee |